Latest research on Celecoxib

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Celecoxib side effects

When mouse were treated with anti-inflammation Celecoxib, the tumor mass was decreased and their life expectancy increased from 28 to 49 days. [source, 2016]
Specifically, Celecoxib and rofecoxib treatment decreases the deposition of Aβ1–42 in AD patients and mouse models4950. [source, 2016]
Although ∼50–70% of C57BL/6 mice died after administration of 180 μg kg−1 TsV, Indomethacin, Celecoxib and EP2 antagonist treatment decreased mortality, PGE2 and IL-1β production and neutrophil infiltration in the lungs (Fig. 4b–d). [source, 2016]
Celecoxib is recognised to increase the risk of cardiovascular thrombotic events, congestive heart failure and major gastrointestinal events compared with placebo,5 and, in the European Union, is contraindicated in patients with known cardiovascular and peripheral vascular disease. [source, 2016]
found that oral Celecoxib caused acid reflux, nausea, and epigastric pain and results also reported in a Cochrane systematic review. [source, 2016]
Celecoxib inhibits the phosphorylation of p38 MAPK, resulting in a decrease of RTA expression. [source, 2015]
Because Celecoxib is a COX-2 inhibitor, we determined whether the COX-2 pathway is involved in KSHV lytic replication. [source, 2015]
To determine whether the inhibitory effect of Celecoxib on RTA expression was due to the decreased number of viral genomes, the levels of RTA expression in BCBL-1 treated with 25 µM Celecoxib were determined by WB at various time points for RTA expression and amplification of KSHV genomes. [source, 2015]
As shown in Figure 5E, Celecoxib dose-dependently decreased RTA promoter activity, indicating that its inhibitory effect on RTA expression directly regulated RTA promoter activation. [source, 2015]
Notably, with the incubation of Celecoxib (25 µM) over time, the activity of the RTA promoter decreased compared to the increase of the control. [source, 2015]